260 related articles for article (PubMed ID: 24503457)
21. Anti-inflammatory effects of macrolides in childhood lung diseases.
Luisi F; Gandolfi TD; Daudt AD; Sanvitto JP; Pitrez PM; Pinto LA
J Bras Pneumol; 2012; 38(6):786-96. PubMed ID: 23288126
[TBL] [Abstract][Full Text] [Related]
22. Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: meta-analysis of randomized controlled trials.
Zhuo GY; He Q; Xiang-Lian L; Ya-Nan Y; Si-Te F
Pulm Pharmacol Ther; 2014 Oct; 29(1):80-8. PubMed ID: 24594263
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulatory effects of macrolide antibiotics - part 2: advantages and disadvantages of long-term, low-dose macrolide therapy.
Altenburg J; de Graaff CS; van der Werf TS; Boersma WG
Respiration; 2011; 81(1):75-87. PubMed ID: 20733282
[TBL] [Abstract][Full Text] [Related]
24. Long-term efficacy of macrolide treatment in idiopathic pulmonary fibrosis: a retrospective analysis.
Kuse N; Abe S; Hayashi H; Kamio K; Saito Y; Usuki J; Azuma A; Kudoh S; Gemma A
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Oct; 33(3):242-246. PubMed ID: 27758989
[TBL] [Abstract][Full Text] [Related]
25. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease.
Rubin BK; Henke MO
Chest; 2004 Feb; 125(2 Suppl):70S-78S. PubMed ID: 14872003
[TBL] [Abstract][Full Text] [Related]
26. Past, present and future of macrolide therapy for chronic rhinosinusitis in Japan.
Shimizu T; Suzaki H
Auris Nasus Larynx; 2016 Apr; 43(2):131-6. PubMed ID: 26441370
[TBL] [Abstract][Full Text] [Related]
27. [Macrolides. Antiinflammatory and immunomodulator effects. Indication in respiratory diseases].
Sacre Hazouri JA
Rev Alerg Mex; 2006; 53(3):108-22. PubMed ID: 16970113
[TBL] [Abstract][Full Text] [Related]
28. N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.
Bosnar M; Kragol G; Koštrun S; Vujasinović I; Bošnjak B; Bencetić Mihaljević V; Marušić Ištuk Z; Kapić S; Hrvačić B; Brajša K; Tavčar B; Jelić D; Glojnarić I; Verbanac D; Culić O; Padovan J; Alihodžić S; Eraković Haber V; Spaventi R
J Med Chem; 2012 Jul; 55(13):6111-23. PubMed ID: 22697905
[TBL] [Abstract][Full Text] [Related]
29. Immunomodulatory effects of macrolide antibiotics in respiratory disease: therapeutic implications for asthma and cystic fibrosis.
Sharma S; Jaffe A; Dixon G
Paediatr Drugs; 2007; 9(2):107-18. PubMed ID: 17407366
[TBL] [Abstract][Full Text] [Related]
30. Immunomodulatory effects of macrolides: implications for practicing clinicians.
Siddiqui J
Am J Med; 2004 Nov; 117 Suppl 9A():26S-29S. PubMed ID: 15586561
[TBL] [Abstract][Full Text] [Related]
31. A review of non-cystic fibrosis bronchiectasis in children with a focus on the role of long-term treatment with macrolides.
El Boustany P; Gachelin E; Colomban C; Cernoia J; Sudour P; Carsin A; Dubus JC
Pediatr Pulmonol; 2019 Apr; 54(4):487-496. PubMed ID: 30652424
[TBL] [Abstract][Full Text] [Related]
32. Inhalation of macrolides: a novel approach to treatment of pulmonary infections.
Siekmeier R; Hofmann T; Scheuch G
Adv Exp Med Biol; 2015; 839():13-24. PubMed ID: 25252902
[TBL] [Abstract][Full Text] [Related]
33. Macrolides in the treatment of asthma and cystic fibrosis.
Ferrara G; Losi M; Franco F; Corbetta L; Fabbri LM; Richeldi L
Respir Med; 2005 Jan; 99(1):1-10. PubMed ID: 15672842
[TBL] [Abstract][Full Text] [Related]
34. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases.
Serisier DJ
Lancet Respir Med; 2013 May; 1(3):262-74. PubMed ID: 24429132
[TBL] [Abstract][Full Text] [Related]
35. Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis.
Wu Q; Shen W; Cheng H; Zhou X
Respirology; 2014 Apr; 19(3):321-9. PubMed ID: 24417869
[TBL] [Abstract][Full Text] [Related]
36. Macrolide antibiotics for cystic fibrosis.
Southern KW
Paediatr Respir Rev; 2012 Dec; 13(4):228-9. PubMed ID: 23069121
[No Abstract] [Full Text] [Related]
37. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.
Zarogoulidis P; Papanas N; Kioumis I; Chatzaki E; Maltezos E; Zarogoulidis K
Eur J Clin Pharmacol; 2012 May; 68(5):479-503. PubMed ID: 22105373
[TBL] [Abstract][Full Text] [Related]
38. Macrolides in cystic fibrosis: is there a role?
Wolter JM; Seeney SL; McCormack JG
Am J Respir Med; 2002; 1(4):235-41. PubMed ID: 14720043
[TBL] [Abstract][Full Text] [Related]
39. Macrolides in the treatment of bronchiolitis obliterans in allograft recipients.
Maimon N; Lipton JH; Chan CK; Marras TK
Bone Marrow Transplant; 2009 Jul; 44(2):69-73. PubMed ID: 19430505
[TBL] [Abstract][Full Text] [Related]
40. Applying lessons learned in the treatment of diffuse panbronchiolitis to other chronic inflammatory diseases.
Kudoh S
Am J Med; 2004 Nov; 117 Suppl 9A():12S-19S. PubMed ID: 15586559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
